Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free CEROW Stock Alerts

CERo Therapeutics (CEROW) Competitors

$0.0017 0.00 (0.00%)
As of 08/25/2026
Compare

CEROW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy CERo Therapeutics stock or one of its competitors? CERo Therapeutics's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CERo Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and CERo Therapeutics (NASDAQ:CEROW) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
CERo Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$491.95MN/AN/AN/AN/A
CERo TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Alvotech had 5 more articles in the media than CERo Therapeutics. MarketBeat recorded 5 mentions for Alvotech and 0 mentions for CERo Therapeutics. Alvotech's average media sentiment score of 0.36 beat CERo Therapeutics' score of 0.00 indicating that Alvotech is being referred to more favorably in the media.

Company Overall Sentiment
Alvotech Neutral
CERo Therapeutics Neutral

Summary

Alvotech beats CERo Therapeutics on 3 of the 3 factors compared between the two stocks.

How does CERo Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLMW) and CERo Therapeutics (NASDAQ:CEROW) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
CERo TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Apollomics had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 1 mentions for Apollomics and 0 mentions for CERo Therapeutics. Apollomics' average media sentiment score of 1.87 beat CERo Therapeutics' score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company Overall Sentiment
Apollomics Very Positive
CERo Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
CERo Therapeutics N/A N/A N/A

Summary

Apollomics beats CERo Therapeutics on 3 of the 3 factors compared between the two stocks.

How does CERo Therapeutics compare to Aravive?

CERo Therapeutics (NASDAQ:CEROW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
CERo Therapeutics Neutral
Aravive Neutral

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aravive beats CERo Therapeutics on 2 of the 2 factors compared between the two stocks.

How does CERo Therapeutics compare to bioAffinity Technologies?

CERo Therapeutics (NASDAQ:CEROW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/AN/AN/AN/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

In the previous week, bioAffinity Technologies had 3 more articles in the media than CERo Therapeutics. MarketBeat recorded 3 mentions for bioAffinity Technologies and 0 mentions for CERo Therapeutics. bioAffinity Technologies' average media sentiment score of 0.30 beat CERo Therapeutics' score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
CERo Therapeutics Neutral
bioAffinity Technologies Neutral

Summary

bioAffinity Technologies beats CERo Therapeutics on 3 of the 3 factors compared between the two stocks.

How does CERo Therapeutics compare to BioVie?

CERo Therapeutics (NASDAQ:CEROW) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A N/A
BioVie N/A N/A N/A

In the previous week, BioVie had 2 more articles in the media than CERo Therapeutics. MarketBeat recorded 2 mentions for BioVie and 0 mentions for CERo Therapeutics. BioVie's average media sentiment score of 0.43 beat CERo Therapeutics' score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company Overall Sentiment
CERo Therapeutics Neutral
BioVie Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

Summary

BioVie beats CERo Therapeutics on 2 of the 2 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CEROW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CEROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CEROW vs. The Competition

Export
MetricCERo TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$4.02B$7.24B$12.90B
Dividend YieldN/A3.63%2.54%11.02%
P/E RatioN/A11.55272.4924.28
Price / SalesN/A1,307.91606.9679.45
Price / CashN/A108.3779.8953.65
Price / BookN/A16.6713.116.27
Net IncomeN/A-$22.76M$3.46B$347.96M
7 Day PerformanceN/A3.68%2.13%1.56%
1 Month PerformanceN/A11.99%8.29%4.80%
1 Year PerformanceN/A58.96%26.58%17.12%

CERo Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CEROW
CERo Therapeutics
N/A$0.00
flat		N/AN/A$0.00N/AN/A8
ALVOW
Alvotech
N/A$0.20
-7.2%		N/A-67.5%$0.00$559.42MN/A4
APLMW
Apollomics
N/A$0.02
-1.9%		N/A-28.4%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.12
+37.7%		N/A+90.0%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CEROW) was last updated on 8/27/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel